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ABSTRACT 
Background: Maternal depression during pregnancy increases risk for adverse developmental 
outcomes in children. However, the underpinning biological mechanisms remain unknown. We tested 
whether depression was associated with levels of and change in inflammatory state during pregnancy, 
if early pregnancy overweight/obesity or diabetes/hypertensive pregnancy disorders accounted 
for/mediated these effects, and if depression added to the inflammation that typically accompanies 
these conditions.  
Methods: We analyzed plasma high-sensitivity C-reactive-protein (hsCRP) and glycoprotein acetyls 
at three consecutive stages during pregnancy, derived history of depression diagnoses before 
pregnancy from Care Register for Healthcare (HILMO) (N=375) and self-reports (N=347) and 
depressive symptoms during pregnancy using the Center for Epidemiological Studies Depression 
Scale completed concurrently to blood samplings (N=295). Data on early pregnancy body mass index 
(BMI) and diabetes/hypertensive pregnancy disorders came from medical records.  
Results: Higher overall hsCRP levels, but not change, during pregnancy were predicted by history 
of depression diagnosis before pregnancy (HILMO: Mean difference [MD]=0.69 Standard 
deviation(SD) units; 95%Confidence Interval(CI)=0.26-1.11, self-report: MD=0.56SDs; 
95%CI=0.17-0.94) and higher depressive symptoms during pregnancy (0.06SD per SD increase; 
95%CI=0.00-0.13). History of depression diagnosis before pregnancy also predicted higher overall 
glycoprotein acetyls (HILMO: MD=0.52SDs; 95%CI=0.12-0.93). These associations were not 
explained by diabetes/hypertensive disorders, but were accounted for and mediated by early 
pregnancy BMI. Furthermore, in obese women, overall hsCRP levels increased as depressive 
symptoms during pregnancy increased (p=0.006 for interaction).  
Conclusions: Depression is associated with a proinflammatory state during pregnancy. These 
associations are mediated by early pregnancy BMI, and depressive symptoms during pregnancy 
aggravate the inflammation related to obesity. 
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Introduction 
Maternal depression during pregnancy, including major depressive disorder (MDD), dysthymia, and 
depressive symptoms, is a major pregnancy complication carrying prevalence rates of 7-20% (Lahti 
et al., 2017, Woody et al., 2017). Maternal depression not only hinders maternal quality of life, but 
is often accompanied by overweight/obesity (Kumpulainen et al., 2018), diabetes and hypertensive 
pregnancy disorders (Fenton and Stover, 2006), and shows high continuity postpartum (Kumpulainen 
et al., 2018). Maternal depression during pregnancy also associates with poorer fetal growth and 
preterm birth (Jarde et al., 2016) and increases child risk for inflammation, allergies, asthma, poorer 
neurodevelopment, and psychopathology (Flanigan et al., 2018, Lahti et al., 2017, Plant et al., 2016, 
Tuovinen et al., 2018, Van den Bergh et al., 2017).  
 
However, the biological mechanisms underlying the transmission of these effects from the mother to 
her child remain vague. In addition to depression-related changes in placental structure and function 
(Lahti-Pulkkinen et al., 2018, Raikkonen et al., 2015, Reynolds et al., 2015), stress axes, oxidative 
stress and nutrition (Glover, 2015, Van den Bergh et al., 2017), it has been suggested that depression 
may aggravate maternal proinflammatory state set forth in pregnancy (Leff-Gelman et al., 2016) and 
link maternal depression with child development (Glover, 2015, Van den Bergh et al., 2017).  
 
By using the Newcastle Ottawa Scale (NOS) (Anthony and Lin, 2018; Herzog et al., 2013; Wells et 
al., 2014a, 2014b), we systematically assessed the quality of evidence of the scant previous studies 
that have tested if depression is associated with inflammation during pregnancy. Table ST1 provides 
a summary of the study characteristics, main findings and NOS quality of evidence assessment. Table 
ST2 provides further details of the NOS assessment and criteria for cross-sectional (Anthony and Lin, 
2018; Herzog et al., 2013) and Table ST3 for cohort studies (Wells et al., 2014a, 2014b). The NOS 
assessment of the reviewed studies highlights the limited quality of available evidence: of the ten 
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reviewed studies 40% were defined as ‘poor’ (Azar and Mercer, 2013, Cheng and Pickler, 2014, 
Gustafsson et al., 2018, Scrandis et al., 2008), 50% as ‘fair’ (Cassidy-Bushrow et al., 2012, Christian 
et al., 2009, Haeri et al., 2013, Osborne et al., 2018, Simpson et al., 2016) and 10% as ‘good’ 
(Blackmore et al., 2011) based on the NOS assessment. Table ST1 also shows that the findings are 
mixed with some studies showing that maternal depression is associated with higher levels of a 
number of inflammatory markers studied and some reporting null associations. In the only study 
providing good quality of evidence, MDD diagnosis and depressive symptoms at 18 and 32 
gestational weeks were not significantly associated with interleukin(IL)-6 or tumor necrosis factor 
alpha (TNF-α) measured at these same gestational weeks (Blackmore et al., 2011). There were no 
longitudinal associations across time between depression and inflammation either (Blackmore et al., 
2011). Our review, thus, highlights the need for further studies with good quality of evidence to either 
refute or confirm the hypothesis that depression aggravates the proinflammatory state set forth in 
pregnancy. 
 
Apart from the limited quality of evidence, there are also critical knowledge gaps in the existing 
literature. The studies are based on small samples limiting statistical power, and all but two (Azar and 
Mercer, 2013, Blackmore et al., 2011) have reported cross-sectional correlations, even if depression 
and/or inflammation would have been measured at more than one gestational stage. In addition to the 
above-mentioned good quality study (Blackmore et al., 2011), the other, small-scale study reporting 
longitudinal associations showed in 27 women that an increase in depressive symptoms from 7-10 to 
16-20 gestational weeks was associated with higher IL-6 at 16-20 gestational weeks, but the increase 
was not associated with c-reactive protein (CRP) or TNF-α (Azar and Mercer, 2013). A further 
knowledge gap relates to the limited evidence available on depression diagnoses: all of the previous 
studies have focused on depressive symptoms and only three (Blackmore et al., 2011, Haeri et al., 
2013, Osborne et al., 2018) have additionally studied depression diagnoses. Moreover, since 
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convincing evidence shows associations between depression and obesity in pregnant populations 
(Kumpulainen et al., 2018, Molyneaux et al., 2014); and inflammatory state in pregnancy is 
aggravated in response to obesity (Choi et al., 2013), most studies on depression and inflammation 
during pregnancy have accounted for pre-pregnancy overweight/obesity (Blackmore et al., 2011, 
Cassidy-Bushrow et al., 2012, Christian et al., 2009, Haeri et al., 2013, Osborne et al., 2018, Simpson 
et al., 2016). However, few studies have considered diabetes and hypertensive pregnancy disorders 
(Azar and Mercer, 2013, Haeri et al., 2013, Osborne et al., 2018, Simpson et al., 2016) even though 
these conditions are associated with depression (Fenton and Stover, 2006), often complicate 
overweight/obese pregnancies (Ovesen et al., 2011) and associate with increased inflammation as 
well (Pantham et al., 2015, Rebelo et al., 2013). Finally, none of the studies have tested whether 
depression adds to the inflammatory effects of overweight/obesity, diabetes and hypertensive 
pregnancy disorders. 
 
To address these knowledge gaps, we tested the hypotheses that 1) history of depression diagnoses 
before pregnancy, derived from healthcare registry, and 2) from self-reports, and 3) higher levels of 
depressive symptoms reported during pregnancy were associated with higher levels of and increases 
in plasma high-sensitive CRP (hsCRP) and glycoprotein acetyls measured across three consecutive 
stages during pregnancy. We also tested the hypotheses that early pregnancy body mass index (BMI), 
diabetes and hypertensive pregnancy disorders accounted for and, at least partially mediated these 
associations, and tested if depression added to the inflammation that accompany these conditions.  
 
We focused on two proinflammatory biomarkers: hsCRP and glycoprotein acetyls, because they both 
have long half-lives and indicate systemic, low-grade chronic inflammation (Ritchie et al., 2015). 
HsCRP is among the most commonly used inflammatory biomarkers in research. Vast evidence in 
the general population supports its longitudinal associations with depression (Copeland et al., 2012, 
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Huang et al., 2019, Valkanova et al., 2013) and cardiovascular mortality (Li et al., 2017). 
Glycoprotein acetyls are, in turn, a novel inflammatory biomarker. It is a composite signal of changes 
in multiple circulating glycoproteins. Glycoprotein acetyls predict the risk of infectious illnesses 
(Ritchie et al., 2015). Importantly, both hsCRP and glycoprotein acetyl levels rise markedly during 
pregnancy (Wang et al., 2016), making them suitable candidate biomarkers for our study.  
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Method 
Sample 
The participants came from the Prediction and Prevention of Pre-eclampsia and Intrauterine Growth 
Restriction (PREDO) Study, described in detail elsewhere (Girchenko et al., 2017). Briefly, in 2005-
2009, 1079 pregnant women were enrolled to the clinical subsample of the PREDO when they arrived 
for their first ultrasound screening at 12-13 weeks of gestation. Of them, 969 had one or more and 
110 none of the known risk factors for pre-eclampsia and intrauterine growth restriction (IUGR). The 
study sites comprised 10 hospitals in Southern and Eastern Finland.  
 
Of the 1079 women, 420 underwent venous blood sampling at one to three consecutive stages during 
pregnancy; due to economic constraints, blood was sampled only at three study hospitals. Because of 
large within-individual variation in the levels of hsCRP and glycoprotein acetyls across the three 
samplings, we did not impute missing data (n=41 with one or two missing blood samples).  
 
Hence, our sample comprised 379 women providing three blood samples taken at median 
(interquartile range) 13.0 (12.6-13.4), 19.3 (19.0-19.7), and 27.0 (26.6-27.6) gestational weeks. 
Health registry data on history of depression diagnoses before pregnancy were available for 375 
women (2 women had no data available and 2 women who received depression diagnosis during 
pregnancy were excluded); 347 had data on self-reported history of depression diagnosis before 
pregnancy (29 did not complete the questionnaire and 3 did not specify when they were diagnosed); 
and 295 women reported depressive symptoms concurrently to the three blood samplings during 
pregnancy (84 did not complete the symptom questionnaire). Women with these three analytic 
samples differed from women of the entire sample only in two respects: they were more often younger 
than 40 years, and less often reported a history of depression diagnosis before pregnancy (Table 1).  
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All participants signed written informed consents. The PREDO study protocol was approved by ethics 
committees of the Helsinki and Uusimaa Hospital District. All study procedures were in accordance 
with The Code of Ethics of the World Medical Association (Declaration of Helsinki). 
 
Inflammation 
The participants came for blood sampling from antecubital vein between 7-9 AM, after having fasted 
for at least 10 hours. Plasma was separated immediately. Ethylenediaminetetraacetic acid plasma 
samples were stored at -80°C until analyzed. The hsCRP concentration (mg/L) was analyzed with a 
Beckman-Coulter CRP immunoturbidometric assay and Olympus AU680 analyzer (Beckman 
Coulter Inc., CA, USA). The intra-assay variation (CV%) of the method in our laboratory was 
between 2.6 % (n=10, mean 1.20 mg/L) and 0.7 % (n=10, mean 65 mg/L) and inter-assay variations 
were (CV%) 3.5 % (n=30, mean 1.07 mg/l), 1. 2 % (n=30, mean 11.5 mg/L) and 2.9% (n=30, mean 
73 mg/L). The limit of detection of the hsCRP method is 0.02 mg/L and the functional sensitivity was 
better than 0.1 mg/L. Glycoprotein acetyls (mmol/L) were analyzed using a high-throughput nuclear 
magnetic resonance metabolomics platform (1HNMR spectra, Nightingale Ltd.; Espoo, Finland) 
(Soininen et al., 2015). 
 
Depression 
We derived depression diagnoses from the Care Register for Healthcare (HILMO), comprising 
diagnoses of all inpatient hospitalizations in Finland since 1969 and outpatient hospitalizations and 
specialized treatments since 1998; participants were born 1959-1989. Depression diagnoses were 
identified with the International Classification of Diseases, Tenth-Revision (ICD-10) codes F32-F33, 
F341 since 1996 and with ICD-9 codes 2961, 2968A, and 3004A in 1987-1995. No women had 
bipolar disorder in our sample. The median time interval between the last hospital discharge with 
depression and conception was 3.1 years (Interquartile Range=1.9-6.7 years). 
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In early pregnancy, the women answered the question “Have you ever been diagnosed by a 
physician with depression?” followed by a question on when they were diagnosed.  
 
Starting from 12-13 gestational weeks, the women completed the Center for Epidemiological Studies 
Depression Scale (CES-D) (Radloff, 1977). The 20 CES-D questions describe depressive symptoms 
during the past week, rated from none (0) to all (3) of the time. The women completed the CES-D 
biweekly up to 14 times until 38-39 gestational weeks or delivery. This allowed us to identify the 
measurements that matched the closest to the three blood samplings for inflammatory biomarkers; 
for each sampling, we identified two CES-D scores closest to the sampling date. We used the average 
of these two scores at the three sampling points in our analyses.  
 
Higher CES-D scores indicate more depressive symptoms, and 16 points or more represent probable 
clinical depression (Radloff, 1977). The CES-D is a well-established measure of depression, and it 
has been validated in pregnant women (Lahti et al., 2017).   
 
Covariates and Moderators 
Early pregnancy body mass index (BMI), calculated from weight [kilograms(kg] and height 
[meters(m)] measurements verified at the first antenatal clinic visit [Mean=8.5, standard deviation 
(SD)=1.5 gestational weeks)], was derived from medical records (overweight[25-29.99 kg/m2]/obese 
[≥30 kg/m2]/normal weight[≤24.99 kg/m2];(WHO, 2000)). Diagnoses of diabetes (type 1 
diabetes/gestational diabetes/no diabetes) and hypertensive (chronic hypertension/pre-
eclampsia/gestational hypertension/normotension) pregnancy disorders were derived from medical 
records and the diagnoses were verified by a clinical jury. Additional covariates included age (<40 
vs. ≥40 years) and smoking during pregnancy (did not smoke vs. quit during first trimester/smoked 
throughout pregnancy), derived from medical records and Finnish Medical Birth Register, and 
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antenatal alcohol use (yes/no) and education level (basic/secondary vs. tertiary), which were reported 
in early pregnancy. 
 
Statistical Analyses 
The primary data analytic tool was linear mixed-model regression with hsCRP and glycoprotein 
acetyls at the three sampling points during pregnancy, analyzed in separate models, as time-varying 
within-person outcomes. History of depression diagnoses before pregnancy from HILMO and self-
reports were treated as time-invariant between-person predictors, and depressive symptoms at the 
three points matching the blood sampling points as a time-varying within-person predictor. In 
addition to treating depressive symptoms during pregnancy as continuous, we conducted analyses 
treating the symptoms as a binary variable indicating probable clinical depression (CES-D ≥16). All 
depression indicators were assessed in separate mixed models, which included gestational week at 
blood sampling as a time-varying within-person predictor and those covariates that were significantly 
associated with hsCRP and/or glycoprotein acetyls. Interactions of depression (diagnoses or 
symptoms) x gestational week at blood samplings were added into the models to test if depression 
predicted changes in hsCRP or glycoprotein acetyls during pregnancy.  
 
We then tested if overweight/obesity, diabetes or hypertensive pregnancy disorders accounted for any 
effects of depression on inflammation by including the main effects of these conditions into separate 
mixed-model equations. If the effect sizes of depression attenuated after adjustment for these 
conditions, we further tested for mediation with the bootstrapping method using 5000 resamples and 
bias corrected 95% confidence intervals. These analyses were performed only if the other criteria for 
mediation were also met: 1) the depression indicator was associated with the condition that attenuated 
the association and 2) the condition in question was associated with the inflammation marker in 
question. Finally, to study if depression added to the inflammatory effects of overweight/obesity, 
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diabetes or hypertensive pregnancy disorders, we included interaction terms depression x normal 
weight/overweight/obesity, depression x diabetes disorders and depression x hypertensive disorders 
into the mixed-model equations.  
 
For mixed-models, we used variance components covariance structure and defined a random intercept 
and random slope for time, i.e., gestational week at blood sampling. Because hsCRP and CES-D 
distributions were skewed, we normalized hsCRP with logarithm and CES-D with square root 
transformations. To facilitate interpretation, we transformed all continuous variables to standard 
deviation (SD) units (for time-varying variables we used the mean of the three data points during 
pregnancy and its SD to retain within-person variation). To facilitate clinical interpretation, we also 
provide test statistics in raw units of hsCRP and glycoprotein acetyls.  
 
We conducted sensitivity analyses by excluding measurements of hsCRP and glycoprotein acetyls 
taken within a month preceding or following acute infectious disease diagnoses derived from HILMO 
to ascertain that acute infection did not affect our results. The sensitivity analyses included 879-1112 
hsCRP and 808-1020 glycoprotein measurements out of the 885-1125 available samples. Infectious 
illnesses were identified with diagnostic codes as described elsewhere (Kohler et al., 2017, Lund-
Sorensen et al., 2016). 
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Results  
Background Characteristics 
Table 1 shows the sample characteristics. HsCRP and glycoprotein acetyls were inter-correlated 
(Pearson r’s≥0.38, p<0.001) and showed high rank-order stability across pregnancy (r≥0.75 for 
hsCRP and r≥0.72 for glycoprotein). Figure ST1 shows that levels of hsCRP (Panel A) and 
glycoprotein acetyls (Panel B) changed during pregnancy; change in hsCRP was A-shaped, whilst 
glycoprotein acetyls increased linearly across pregnancy. HILMO and self-reported history of 
depression diagnosis before pregnancy showed concordance (kappa=0.47, p<0.001), and both were 
associated with higher levels of depressive symptoms during pregnancy (diagnosis from HILMO: 
Mean Difference[MD]=1.00 SD, 95%CI=0.44-1.56, p=0.001; diagnosis from self-reports: MD=1.09 
SD, 95%CI=0.64-1.53, p<0.001) and with higher prevalence of probable clinical depression during 
pregnancy (diagnosis from HILMO: 66.7% vs. 19.4%, p<0.001; diagnosis from self-reports: 57.9% 
vs. 18.4%, p<0.001). 
  
Table ST4 shows that women with lower education, who were overweight or obese in early pregnancy 
or had chronic hypertension, pre-eclampsia or gestational diabetes had higher overall hsCRP and 
glycoprotein acetyl levels. HsCRP levels were also higher and changed less across pregnancy in 
women younger than 40 years (β=0.013 in older and β=-0.006 in younger women; p=0.01 for age x 
time interaction). Glycoprotein acetyls increased more across pregnancy in overweight than normal 
weight women (β=0.08 in overweight and β=0.07 in normal weight women; p=0.01 for normal weight 
vs. overweight x time interaction). Smoking, alcohol use during pregnancy or type 1 diabetes were 
not associated with hsCRP or glycoprotein acetyls (Table ST4). 
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Depression and Inflammation during Pregnancy 
Table 2 shows that hsCRP levels were 0.69 SDs (Mean difference in raw units [MD]=4.11, 95% 
Confidence Interval [CI]=2.54-5.69 mg/L) and 0.56 SDs (MD=2.44, 95%CI=1.12-3.77 mg/L) higher 
in women with compared to those without a history of depression diagnosis before pregnancy derived 
from HILMO and self-reports, respectively; hsCRP levels were also 0.28 SDs (MD=1.02, 
95%CI=0.17-1.88 mg/L) higher in women with compared to those without probable clinical 
depression during pregnancy, and 0.06 SDs higher per each SD increase in these symptoms during 
pregnancy. Glycoprotein acetyls were 0.52 SDs (MD=1.02, 95%CI=0.17-1.88 mg/L) higher in 
women with compared to those without a history of depression diagnosis from HILMO and 0.25 SDs 
(MD=0.05, 95%CI=0.003-0.09 mg/L) higher in women with compared to those without probable 
clinical depression during pregnancy. All associations, except for probable clinical depression during 
pregnancy with glycoprotein acetyls, remained significant when adjusted for age and education 
(Table 2) and when adjusted for diabetes and hypertensive pregnancy disorders (Table ST5). 
However, all associations became non-significant when adjusted for early pregnancy BMI (Table 2). 
In the models where depression no longer associated with hsCRP, overweight (MD=0.54 SDs 
between normal weight vs. overweight, 95%CI=0.31-0.97) and obesity (MD=1.01 SDs between 
normal weight vs. obesity, 95%CI=0.80-1.22) remained significant predictors of hsCRP (respective 
values for glycoprotein acetyls were MD=0.73 SDs, 95%CI=0.51-0.97 and MD=0.93 SDs, 
95%CI=0.51-1.18).  Figures 1-2 display that there were no depression x gestational week at blood 
sampling interactions. 
 
The exclusion of hsCRP and glycoprotein measurements taken within one month preceding or 
following diagnosed infectious diseases did not change the associations (Table ST6). 
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Mediation  
Figures ST2--ST4 show that early pregnancy BMI mediated the following effects on hsCRP: history 
of depression diagnosis before pregnancy from HILMO and from self-reports, and depressive 
symptoms reported during pregnancy. Figure ST5 shows that BMI also mediated the effect of history 
of depression diagnosis before pregnancy from HILMO on glycoprotein acetyls. We did not test other 
possible mediation effects, as the criteria for mediation tests were not met.  
 
Additive Effects 
We found one significant interaction: depressive symptoms during pregnancy interacted significantly 
with normal weight vs. obesity in the analysis of hsCRP (p=0.006 for interaction; p=0.57 for 
depressive symptoms x normal weight vs. overweight interaction). Figure 3 shows that higher 
depressive symptoms during pregnancy were associated with higher hsCRP levels in obese women, 
but not in overweight or normal weight women. This may reflect that below BMI 30kg/m2 hsCRP 
increased with increasing BMI, but at BMI 30kg/m2 and above hsCRP plateaued showing no further 
increase (Figure ST6).    
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Discussion 
We found that depression was associated with higher levels of hsCRP and glycoprotein acetyls during 
pregnancy. The findings for hsCRP were consistent and significant across the different information 
sources of depression; whether history of depression diagnosis before pregnancy was derived from 
HILMO or self-reports, or whether depressive symptoms were reported during pregnancy concurrent 
to the three consecutive blood samplings, and treated either as a continuous or a binary variable, the 
latter indicating probable clinical depression during pregnancy. The pattern of findings on 
glycoprotein acetyls was also consistent across the different information sources, but reached 
conventional significance levels for the history of depression diagnosis before pregnancy derived 
from HILMO and for the probable clinical depression reported during pregnancy.  
 
While hsCRP and glycoprotein acetyl levels changed modestly during pregnancy, the associations 
between depression and these inflammatory biomarkers did not vary across pregnancy. The level of 
these inflammatory biomarkers have, however, been shown to be markedly higher among women 
who are than who are not pregnant (Wang et al., 2016). In line, another study has reported that in 
pregnant women the mean hsCRP levels were above 10 mg/L at 10.6 gestational weeks (Berggren et 
al., 2015), and yet another study has reported that over 50% of non-pregnant 31-year-old women have 
hsCRP values below 1.0 mg/L (Liukkonen et al., 2011).  
 
Our findings associating depression with higher inflammation among pregnant women correspond 
with meta-analytic findings from the general population showing longitudinal associations between 
depression and higher hsCRP and IL-6 levels (Valkanova et al., 2013). Furthermore, in our study the 
degree of inflammation related to depression was of comparable magnitude to the inflammation 
associated with early pregnancy overweight, gestational diabetes, and pre-eclampsia. Only the effects 
of early pregnancy obesity exceeded the degree of depression-related inflammation during pregnancy. 
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In raw units, mean differences in hsCRP levels between women with and without depression 
diagnosis before pregnancy and with and without probable clinical depression during pregnancy were 
between 1.02 and 4.11 mg/L. This magnitude of inflammation is comparable to the degree of 
inflammation that has been suggested to increase cardiovascular disease risk moderately in the 
general population (Li et al., 2017). These findings suggest that depression is associated with a higher 
proinflammatory state during pregnancy, bearing at least moderate clinical relevance to maternal 
health and possibly fetal development. To our knowledge, our prospective study is the largest on this 
topic in sample size thus far, and the first to show such associations using information on depression 
derived from different sources and three consecutive stages during pregnancy. 
 
The associations between the different depression measures with hsCRP and glycoprotein acetyls 
were independent of age, education, diabetes and hypertensive pregnancy disorders. However, early 
pregnancy BMI accounted for and mediated the effects of depression diagnosis before pregnancy and 
depressive symptoms during pregnancy on inflammation. The mediation via BMI is not surprising, 
since early pregnancy overweight/obesity and antenatal depression are highly interrelated 
(Kumpulainen et al., 2018, Molyneaux et al., 2014). Nevertheless, since depression and obesity show 
continuity across time (Kumpulainen et al., 2018, Simmonds et al., 2016), and the depression-BMI-
association is bi-directional (Luppino et al., 2010), we cannot disentangle whether 
overweight/obesity preceded depression, or vice versa. Therefore, the mediation findings must be 
interpreted with caution.  
 
We also found that depressive symptoms during pregnancy added to the inflammatory effects of 
obesity: among obese women, who had already approximately 1SD higher hsCRP levels throughout 
pregnancy, hsCRP increased further by 0.19 SDs by each SD increase in depressive symptoms during 
pregnancy. In overweight and normal weight women, this was not true. Based on the nature of the 
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association we found between BMI and hsCRP, we speculate that the strong linear association 
between BMI and hsCRP between 20 and 30 kg/m2 leaves no room for depression to independently 
predict hsCRP in normal weight and overweight women. However, our data suggests that in obese 
women hsCRP reaches a ceiling: at 30 kg/m2 and above hsCRP levels plateau, remain consistently 
high, no longer increasing with increasing BMI. This leaves room for the effects of depressive 
symptoms, which increase inflammation in obese women even further. Corresponding interactions 
between obesity and depression on inflammation have also been reported in non-pregnant populations 
(Ladwig et al., 2003), but our findings are inconsistent with findings from one study of pregnant 
women that were ethnically diverse from our sample (Cassidy-Bushrow et al., 2012).  
 
Obesity is a well-known proinflammatory state (Choi et al., 2013, Pantham et al., 2015) with the 
perturbation of intestinal microbiota and changes in intestinal permeability being potential triggers of 
inflammation (Cox et al., 2015). The secretion of inflammatory cytokines from adipose tissue leads 
to overexpression of pro-inflammatory cytokines (Hotamisligil, 2006). Obesity indeed mediated most 
effects of depression on inflammation in our study. However, since inflammation levels increased 
even further in obese women with higher depressive symptoms during pregnancy, also other factors 
associated with both depression and inflammation may have contributed to our findings. Genetics 
and epigenetics and their interactions may contribute, since depression has been associated with both 
the single-nucleotide polymorphisms and expression of genes regulating inflammatory function 
(Barnes et al., 2017, Mahajan et al., 2018). These factors may also contribute to the interactions 
between obesity and depression on inflammation, since evidence suggests shared genetic origins of 
obesity and depression (Wray et al., 2018). Hypothalamic-pituitary-adrenal (HPA) axis activity may 
also be involved. Glucocorticoids regulate inflammation by exacerbating the secretion of pro-
inflammatory cytokines and acute phase proteins (Pariante, 2017) and have both pro- and anti-
inflammatory effects in the brain (Walker and Spencer, 2018). Glucocorticoid functioning is also 
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closely associated with depression and obesity (Boggero et al., 2017, Milaneschi et al., 2018, Stetler 
and Miller, 2011). Findings in smaller subsamples of the PREDO study suggest that depressive 
symptoms during pregnancy are associated with placental mRNA level changes in genes regulating 
HPA axis function (Raikkonen et al., 2015, Reynolds et al., 2015). The gut microbiota-brain axis 
functioning is also intertwined with inflammatory processes, and changes in its function are 
associated with depression (Alam et al., 2017). Furthermore, depression, obesity and inflammation 
are each also associated with poorer nutrition, insufficient sleep, physical inactivity and substance 
use (Ironson et al., 2018, Lai et al., 2015, Lai et al., 2014, Milaneschi et al., 2018, Stubbs et al., 
2018). A large Mendelian randomization study found that while CRP concentrations were associated 
with depression, genetic variation regulating CRP was not (Wium-Andersen et al., 2014). This 
finding argues against a causal pathway from inflammation to depression and suggests that a common 
‘residual confounding’ factor may possibly underlie the associations found. Hence, the 
proinflammatory effects of depression and obesity likely stem from multiple contributory factors. 
Our findings emphasize the need for further studies on these pathways specifically during pregnancy.  
    
Strengths of our study include a large sample size compared to the previous studies, which often 
included less than 100 participants. We had data on depression from different sources and hsCRP and 
glycoprotein acetyls were measured at three consecutive stages during pregnancy, which no previous 
study has had. Furthermore, many previous studies on depression and inflammation during pregnancy 
utilized very rapidly degrading inflammatory markers, most commonly IL-6. HsCRP is an acute-
phase protein with a longer half-life than IL-6 (Wirtz et al., 2000) and glycoprotein acetyls display 
even slower kinetics than hsCRP. Thus, we were able to obtain more stable estimates of the 
participants’ inflammatory state across pregnancy (Ritchie et al., 2015). While the increases in hsCRP 
and glycoprotein acetyls in pregnancy (Wang et al., 2016) suggest they are suitable markers of 
antenatal inflammation, having data also on other inflammatory biomarkers would have given further 
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insight on the associations of depression and antenatal inflammation. Since glycoprotein acetylation 
is a mix of a range of proteins (Ritchie et al., 2015), we would also have benefited from data on the 
specific protein levels. It would also have been informative to have cortisol data to indicate HPA axis 
activity and other biomarkers that are triggered by inflammation. 
 
The study limitations also include that our sample comprised women at risk for pre-eclampsia and 
IUGR and that blood samples were available only for a subsample. Furthermore, although diagnostic 
data from HILMO were available for 99.5% of women with three blood samples, self-reported 
diagnostic data were available for 91.6% and depressive symptoms were reported by 77.8% of the 
women. The analytic samples comprised women who were younger and less often self-reported a 
history of depression diagnoses before pregnancy. These factors limit generalizations of our findings 
to other samples. 
 
In conclusion, our study showed that depression is associated with a proinflammatory state during 
pregnancy. These associations are mediated by early pregnancy BMI, and depressive symptoms 
during pregnancy aggravate the inflammation related to obesity. 
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Table 1. Characteristics of the sample. 
 Entire sample (N=1079) 
Sample with 3 high-sensitivity C-
reactive protein blood samples and 
data on history of depression 
diagnosis before pregnancy from 
HILMO (N=375) 
Sample with 3 high-sensitivity C-
reactive protein blood samples and 
data on depression diagnosis before 
pregnancy from self-reports (N=347) 
Sample with 3 high-sensitivity C-
reactive protein blood samples and 
data on depressive symptoms reported 
concurrently to the blood samplings 
during pregnancy (N=295) 
 
Mean/N 
(SD/%) 
Range 
Mean/N 
(SD/%) 
Range P1 
Mean/N 
(SD/%) 
Range P2 
Mean/N 
(SD/%) 
Range P3 
Age (years) 33.2 (5.8) 17.2-47.4 32.6 (5.2) 19.5-47.4 0.14 32.6 (5.1) 19.5-47.4 0.08 32.6 (5.1) 20.3-47.4 0.11 
    < 40 years, n (%) 902 (83.6%)  337 (89.9%)  0.003 312 (89.9%)  0.006 265 (89.8%)  0.008 
    ≥ 40 years, n (%) 177 (16.4%)  38 (10.1%)   35 (10.1%)   30 (10.2%)   
    Data not available, n (%) 0  0   0   0   
Education     0.71   0.46   0.79 
    Lower secondary or lower 483 (46.1%)  181 (48.7%)   169 (48.7%)   139 (47.1%)   
    Upper secondary or tertiary 564 (53.9%)  191 (51.3%)   178 (51.3%)   156 (52.9%)   
    Data not available, n (%) 32   3   0   0   
    Data not available, n (%) 0  0   0   0   
Smoking during pregnancy     0.49   0.46   0.80 
   No 1025 (95.4%)  351 (93.9%)   324 (93.6%)   277 (94.2%)   
   Quit during first trimester 39 (3.6%)  17 (4.6%)   17 (4.9%)   14 (4.8%)   
   Smoked throughout pregnancy 11 (1.0%)  6 (1.6%)   5 (1.5%)   3 (1.0%)   
   Data not available, n (%) 4  1   1   1    
Alcohol use during pregnancy     0.23   0.30   0.10 
   No 776 (71.9%)  295 (86.0%)   285 (85.6%)   252 (87.2%)   
   Yes 158 (14.6%)  48 (14.0%)   48 (14.4%)   37 (12.8%)   
   Data not available, n (%) 145   32    14    6    
Body Mass Index in early 
pregnancy(kg/m2) 
27.4 (6.5) 17.2-55.0 27.1 (6.6) 17.6-55.0 0.44 27.1 (6.7) 17.6-55.0 0.46 26.7 (6.7) 17.7-55.0 0.10 
   Normal weight (<24.99 kg/m2) 503 (46.6%)  183 (48.8%)  0.15 171 (49.3%)  0.26 153 (51.9%)  0.08 
   Overweight (25-29.99 kg/m2) 193 (17.9%)  78 (20.8%)   69 (19.9%)   58 (19.7%)   
   Obese (≥30 kg/m2) 383 (35.5%)  114 (30.4%)   107 (30.8%)   84 (28.5%)   
   Data not available, n (%) 0  0   0   0   
Hypertensive disorders in 
pregnancy  
    0.87   0.32   0.37 
    Normotension 705 (65.5%)  237 (63.2%)   222 (64.1%)   192 (65.1%)   
 29 
    Gestational hypertension  108 (10.0%)  36 (9.6%)   34 (9.8%)   31 (10.5%)   
    Pre-eclampsia  98 (9.1%)  37 (9.9%)   33 (9.5%)   24 (8.1%)   
    Chronic hypertension 168 (15.6%)  65 (17.3%)   58 (16.7%)   48 (16.3%)   
    Data not available, n (%) 0  0   0   0   
Diabetes disorders in pregnancy     0.66   0.60   0.20 
    No 818 (75.8%)  288 (76.8%)   268 (77.2%)   233 (79.0%)   
    Gestational diabetes 239 (22.2%)  78 (20.8%)   72 (20.8)   55 (18.6%)   
    Type 1 diabetes 22 (2.0%)  9 (2.4%)   7 (2.0%)   7 (2.4%)   
   Data not available, n (%) 0  0   0   0   
History of depression diagnosis 
before pregnancy 
    0.81   0.64   0.20 
    from HILMO            
             No 1033 (96.1%)  357 (95.2%)   329 (95.1%)   281 (95.9%)   
             Yes 39 (3.6%)  18 (4.8%)   17 (4.9%)   12 (4.1%)   
             Data not available, n (%) 4  0   1   2   
    from self-reports     0.04   0.04   0.07 
             No 827 (89.6%)  322 (93.3%)   324 (93.4%)   261 (93.2%)   
             Yes 96 (10.4%)  23 (6.7%)   23 (6.6%)   19 (6.8%)   
             Data not available, n (%) 156   30    0   15    
Depressive symptoms 
during pregnancy  
           
    continuous score (mean of 
    reports at 3 blood 
    sampling points) 
11.61 (7.05)  0.5-44.7 11.51 (7.11)  0.3-45.0 0.72 11.54  (7.15) 0.33-45.0 0.76 10.58 (10.5) 0.33-45.0 0.78 
    binary score (continuous 
    score≥16, probable clinical 
    depression) 
    0.80   0.99   0.87 
              No 609 (78.9%)  229 (78.7%)   221 (78.9%)   231 (78.3%)   
              Yes 163 (21.1%)  62 (21.3%)   59 (21.1%)   64 (21.7%)   
              Data not available, n (%) 307  84   67    0   
High-sensitivity C-reactive 
protein (mg/L), Median 
(Interquartile Range) 
           
   First sampling point 
  (11.1-16.7 gestational weeks) 
3.81 (2.18-7.34) 0.23-32.70 3.83 (2.22-7.40) 0.23-32.70 0.86 3.80 (2.12-7.34) 0.23-32.70 0.94 3.80 (2.12-7.11) 0.23-31.49 0.90 
   Data not available, n (%) 669  0   0   0   
   Second sampling point 4.53 (2.42-8.69) 0.31-60.65 4.56 (2.37-8.95) 0.31-60.65 0.83 4.50 (2.33-8.71) 0.31-60.65 0.83 4.30 (2.30-7.97) 0.31-60.65 0.48 
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   (17.1-22.9 gestational weeks) 
   Data not available, n (%) 674  0   0   0   
   Third sampling point 
   (25.3-31.1 gestational weeks) 
3.95 (2.11-6.91) 0.19-61.07 3.81 (2.05-6.93) 0.19-61.07 0.68 3.73 (2.00-6.59) 0.19-28.15 0.39 3.72 (1.98-6.37) 0.22-26.10 0.39 
   Data not available, n (%) 677  0   0   0   
Glycoprotein acetyls  (mmol/l)*            
   First sampling point  
   (11.1-16.7 gestational weeks) 
1.26 (0.16) 0.89-1.85 1.27 (0.16) 0.89-1.85 0.40 1.26 (0.16) 0.89-1.85 1.0 1.25 (0.15) 0.89-1.85 0.42 
   Data not available, n (%) 680  31   31   24   
   Second sampling point  
   (17.1-22.9 gestational weeks) 
1.34 (0.18) 0.94-2.14 1.35 (0.17) 1.0-2.14 0.44 1.35 (0.17) 1.0-2.14 0.45 1.34 (0.17) 1.0-2.14 >0.999 
   Data not available, n (%) 679  31   31   24   
   Third sampling point  
   (25.3-31.1 gestational weeks) 
1.45 (0.18) 1.06-2.25 1.45 (0.18) 1.06-2.25 1.0 1.44 (0.17) 1.06-2.25 0.45 1.44 (0.17) 1.06-2.25 0.47 
   Data not available, n (%) 688  31   31   24   
Depressive symptoms during pregnancy in the entire sample are reported as the mean of all available observations, and for the analytic samples as the mean of depressive symptom scores 
measured at the time of the three blood samplings during pregnancy. 
P1 reflects p-value from the analyses exploring difference between the entire sample (N=1079) and the sample with data on history of depression diagnosis before pregnancy derived from 
HILMO (N=375). 
P2 reflects p-value from the analyses exploring difference between the entire sample (N=1079) and the sample with data on history of depression diagnosis before pregnancy derived from self-
reports (N=348). 
P3 reflects p-value from the analyses exploring difference between the entire sample (N=1079) and the sample with data on depressive symptoms reported (Center for Epidemiological Studies 
Depression Scale) at the time of the three blood samplings during pregnancy (N=295). 
*For glycoprotein acetyls, the analytic samples comprised 344, 317 and 271 women with 3 blood samples with glycoprotein acetyls and history of depression diagnosis before pregnancy from 
HILMO and from self-reports and depressive symptoms reported concurrent to the blood samplings during pregnancy, respectively. 
HILMO refers to Care Register for Healthcare. 
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Table 2. Associations of a history of depression diagnosis before pregnancy derived from the Care Register for Healthcare (HILMO) and self-reports, and depressive symptoms 
and probable clinical depression reported during pregnancy with high sensitivity C-Reactive protein and glycoprotein acetyls across the three measurement points during 
pregnancy. 
  
Model 1 
 
Model  2 
 
Model 3 
Estimate in 
SD units* 
95% CI P 
Estimate in 
SD units* 
95% CI P 
Estimate in 
SD units* 
95% CI P 
High-sensitivity C-reactive protein (SD units) (outcome) 
History of depression diagnosis 
before pregnancy (yes vs. no) 
         
    from HILMO 0.69 0.26, 1.11 0.002 0.50 0.08, 0.92 0.02 0.16 -0.21, 0.53 0.40 
    from self-reports 0.56 0.17, 0.94 0.005 0.47 0.10, 0.85 0.01 0.28 -0.05, 0.60 0.09 
Depressive symptoms  
during pregnancy 
         
    continuous score (SD units) 0.06 0.00, 0.13 0.05 0.06 0.00, 0.13 0.05 0.05 -0.01, 0.11 0.14 
    binary score (continuous 
    score≥16, probable clinical 
    depression vs. continuous 
    score<16, no probable clinical 
    depression) 
0.28 0.03, 0.53 0.03 0.28 0.04, 0.52 0.02 0.20 -0.01, 0.42 0.06 
Glycoprotein acetyls (SD units) (outcome) 
History of depression diagnosis 
before pregnancy (yes vs. no) 
         
    from HILMO 0.52 0.12, 0.93 0.01 0.42 0.01, 0.84 0.04 0.04 -0.32, 0.39 0.84 
    from self-reports 0.30 -0.06, 0.66 0.10 0.24 -0.11, 0.60 0.18 0.04 -0.26, 0.34 0.78 
Depressive symptoms  
during pregnancy 
         
    continuous score (SD units) 0.05 -0.01, 0.11 0.10 0.05 -0.01, 0.11 0.10 0.04 -0.02, 0.09 0.23 
    binary score (continuous 
    score≥16, probable clinical 
    depression vs. continuous 
    score<16, no probable clinical 
    depression) 
0.25 0.02, 0.46 0.04 0.25 0.02, 0.48 0.03 0.19 -0.008, 0.38 0.06 
Note. *Estimates and 95% Confidence Intervals (95% CI) reflect differences between those with and without a history of depression diagnosis before pregnancy or with and 
without probable clinical depression during pregnancy in high-sensitivity C-reactive protein (hsCRP) and glycoprotein acetyls in standard deviation (SD) units or change in SD 
units in hsCRP and glycoprotein acetyls per SD unit change in the continuous depressive symptom scores during pregnancy.   
Model 1 is unadjusted for covariates but includes the gestational week when blood was sampled as a within-person time-varying predictor, Model 2 is Model 1 + age and 
education, Model 3 is Model 2 + body mass index in early pregnancy (categorized as normal weight [<25 kg/m2], overweight [25-29.99 kg/m2] and obese [≥30kg/m2]).  
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Figure Legends 
Figure 1.   
Associations between history of depression diagnosis before pregnancy from the Care Register for 
Healthcare (HILMO) (Panel A; P=0.37 for interaction with gestational week at blood sampling) and 
from self-reports (Panel B; P=0.99 for interaction with gestational week at blood sampling) and 
probable clinical depression during pregnancy (Panel C; P=0.62 for interaction with gestational week 
at blood sampling) and high-sensitivity C-reactive protein across the three measurement points during 
pregnancy.  
Figure 2. 
Associations between 1) history of depression diagnosis before pregnancy from the Care Register for 
Healthcare (HILMO) (Panel A; P=0.60 for interaction with gestational week at blood sampling) and 
2) probable clinical depression during pregnancy (Panel C; P=0.70 for interaction with gestational 
week at blood sampling) and glycoprotein acetyls across the three measurement points during 
pregnancy.  
Figure 3. 
Associations between depressive symptoms during pregnancy and high-sensitivity C-reactive protein 
during pregnancy in women who in early pregnancy were normal weight (body mass index[BMI]< 
25 kg/m2), overweight (BMI 25-29.99 kg/m2) or obese (BMI≥ 30 kg/m2).  
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Table 1. Characteristics of the sample. 
 Entire sample (N=1079) 
Sample with 3 high-sensitivity C-
reactive protein blood samples and 
data on history of depression 
diagnosis before pregnancy from 
HILMO (N=375) 
Sample with 3 high-sensitivity C-
reactive protein blood samples and 
data on depression diagnosis before 
pregnancy from self-reports (N=347) 
Sample with 3 high-sensitivity C-
reactive protein blood samples and 
data on depressive symptoms reported 
concurrently to the blood samplings 
during pregnancy (N=295) 
 
Mean/N 
(SD/%) 
Range 
Mean/N 
(SD/%) 
Range P1 
Mean/N 
(SD/%) 
Range P2 
Mean/N 
(SD/%) 
Range P3 
Age (years) 33.2 (5.8) 17.2-47.4 32.6 (5.2) 19.5-47.4 0.14 32.6 (5.1) 19.5-47.4 0.08 32.6 (5.1) 20.3-47.4 0.11 
    < 40 years, n (%) 902 (83.6%)  337 (89.9%)  0.003 312 (89.9%)  0.006 265 (89.8%)  0.008 
    ≥ 40 years, n (%) 177 (16.4%)  38 (10.1%)   35 (10.1%)   30 (10.2%)   
    Data not available, n (%) 0  0   0   0   
Education     0.71   0.46   0.79 
    Lower secondary or lower 483 (46.1%)  181 (48.7%)   169 (48.7%)   139 (47.1%)   
    Upper secondary or tertiary 564 (53.9%)  191 (51.3%)   178 (51.3%)   156 (52.9%)   
    Data not available, n (%) 32   3   0   0   
    Data not available, n (%) 0  0   0   0   
Smoking during pregnancy     0.49   0.46   0.80 
   No 1025 (95.4%)  351 (93.9%)   324 (93.6%)   277 (94.2%)   
   Quit during first trimester 39 (3.6%)  17 (4.6%)   17 (4.9%)   14 (4.8%)   
   Smoked throughout pregnancy 11 (1.0%)  6 (1.6%)   5 (1.5%)   3 (1.0%)   
   Data not available, n (%) 4  1   1   1    
Alcohol use during pregnancy     0.23   0.30   0.10 
   No 776 (71.9%)  295 (86.0%)   285 (85.6%)   252 (87.2%)   
   Yes 158 (14.6%)  48 (14.0%)   48 (14.4%)   37 (12.8%)   
   Data not available, n (%) 145   32    14    6    
Body Mass Index in early 
pregnancy(kg/m2) 
27.4 (6.5) 17.2-55.0 27.1 (6.6) 17.6-55.0 0.44 27.1 (6.7) 17.6-55.0 0.46 26.7 (6.7) 17.7-55.0 0.10 
   Normal weight (<24.99 kg/m2) 503 (46.6%)  183 (48.8%)  0.15 171 (49.3%)  0.26 153 (51.9%)  0.08 
   Overweight (25-29.99 kg/m2) 193 (17.9%)  78 (20.8%)   69 (19.9%)   58 (19.7%)   
   Obese (≥30 kg/m2) 383 (35.5%)  114 (30.4%)   107 (30.8%)   84 (28.5%)   
   Data not available, n (%) 0  0   0   0   
Hypertensive disorders in 
pregnancy  
    0.87   0.32   0.37 
    Normotension 705 (65.5%)  237 (63.2%)   222 (64.1%)   192 (65.1%)   
Table 1 Click here to access/download;Table(s);Table 1 05062019.docx
    Gestational hypertension  108 (10.0%)  36 (9.6%)   34 (9.8%)   31 (10.5%)   
    Pre-eclampsia  98 (9.1%)  37 (9.9%)   33 (9.5%)   24 (8.1%)   
    Chronic hypertension 168 (15.6%)  65 (17.3%)   58 (16.7%)   48 (16.3%)   
    Data not available, n (%) 0  0   0   0   
Diabetes disorders in pregnancy     0.66   0.60   0.20 
    No 818 (75.8%)  288 (76.8%)   268 (77.2%)   233 (79.0%)   
    Gestational diabetes 239 (22.2%)  78 (20.8%)   72 (20.8)   55 (18.6%)   
    Type 1 diabetes 22 (2.0%)  9 (2.4%)   7 (2.0%)   7 (2.4%)   
   Data not available, n (%) 0  0   0   0   
History of depression diagnosis 
before pregnancy 
    0.81   0.64   0.20 
    from HILMO            
             No 1033 (96.1%)  357 (95.2%)   329 (95.1%)   281 (95.9%)   
             Yes 39 (3.6%)  18 (4.8%)   17 (4.9%)   12 (4.1%)   
             Data not available, n (%) 4  0   1   2   
    from self-reports     0.04   0.04   0.07 
             No 827 (89.6%)  322 (93.3%)   324 (93.4%)   261 (93.2%)   
             Yes 96 (10.4%)  23 (6.7%)   23 (6.6%)   19 (6.8%)   
             Data not available, n (%) 156   30    0   15    
Depressive symptoms 
during pregnancy  
           
    continuous score (mean of 
    reports at 3 blood 
    sampling points) 
11.61 (7.05)  0.5-44.7 11.51 (7.11)  0.3-45.0 0.72 11.54  (7.15) 0.33-45.0 0.76 10.58 (10.5) 0.33-45.0 0.78 
    binary score (continuous 
    score≥16, probable clinical 
    depression) 
    0.80   0.99   0.87 
              No 609 (78.9%)  229 (78.7%)   221 (78.9%)   231 (78.3%)   
              Yes 163 (21.1%)  62 (21.3%)   59 (21.1%)   64 (21.7%)   
              Data not available, n (%) 307  84   67    0   
High-sensitivity C-reactive 
protein (mg/L), Median 
(Interquartile Range) 
           
   First sampling point 
  (11.1-16.7 gestational weeks) 
3.81 (2.18-7.34) 0.23-32.70 3.83 (2.22-7.40) 0.23-32.70 0.86 3.80 (2.12-7.34) 0.23-32.70 0.94 3.80 (2.12-7.11) 0.23-31.49 0.90 
   Data not available, n (%) 669  0   0   0   
   Second sampling point 4.53 (2.42-8.69) 0.31-60.65 4.56 (2.37-8.95) 0.31-60.65 0.83 4.50 (2.33-8.71) 0.31-60.65 0.83 4.30 (2.30-7.97) 0.31-60.65 0.48 
   (17.1-22.9 gestational weeks) 
   Data not available, n (%) 674  0   0   0   
   Third sampling point 
   (25.3-31.1 gestational weeks) 
3.95 (2.11-6.91) 0.19-61.07 3.81 (2.05-6.93) 0.19-61.07 0.68 3.73 (2.00-6.59) 0.19-28.15 0.39 3.72 (1.98-6.37) 0.22-26.10 0.39 
   Data not available, n (%) 677  0   0   0   
Glycoprotein acetyls  (mmol/l)*            
   First sampling point  
   (11.1-16.7 gestational weeks) 
1.26 (0.16) 0.89-1.85 1.27 (0.16) 0.89-1.85 0.40 1.26 (0.16) 0.89-1.85 1.0 1.25 (0.15) 0.89-1.85 0.42 
   Data not available, n (%) 680  31   31   24   
   Second sampling point  
   (17.1-22.9 gestational weeks) 
1.34 (0.18) 0.94-2.14 1.35 (0.17) 1.0-2.14 0.44 1.35 (0.17) 1.0-2.14 0.45 1.34 (0.17) 1.0-2.14 >0.999 
   Data not available, n (%) 679  31   31   24   
   Third sampling point  
   (25.3-31.1 gestational weeks) 
1.45 (0.18) 1.06-2.25 1.45 (0.18) 1.06-2.25 1.0 1.44 (0.17) 1.06-2.25 0.45 1.44 (0.17) 1.06-2.25 0.47 
   Data not available, n (%) 688  31   31   24   
Depressive symptoms during pregnancy in the entire sample are reported as the mean of all available observations, and for the analytic samples as the mean of depressive symptom scores 
measured at the time of the three blood samplings during pregnancy. 
P1 reflects p-value from the analyses exploring difference between the entire sample (N=1079) and the sample with data on history of depression diagnosis before pregnancy derived from 
HILMO (N=375). 
P2 reflects p-value from the analyses exploring difference between the entire sample (N=1079) and the sample with data on history of depression diagnosis before pregnancy derived from self-
reports (N=348). 
P3 reflects p-value from the analyses exploring difference between the entire sample (N=1079) and the sample with data on depressive symptoms reported (Center for Epidemiological Studies 
Depression Scale) at the time of the three blood samplings during pregnancy (N=295). 
*For glycoprotein acetyls, the analytic samples comprised 344, 317 and 271 women with 3 blood samples with glycoprotein acetyls and history of depression diagnosis before pregnancy from 
HILMO and from self-reports and depressive symptoms reported concurrent to the blood samplings during pregnancy, respectively. 
HILMO refers to Care Register for Healthcare. 
 
Table 2. Associations of a history of depression diagnosis before pregnancy derived from the Care Register for Healthcare (HILMO) and self-reports, and depressive symptoms 
and probable clinical depression reported during pregnancy with high sensitivity C-Reactive protein and glycoprotein acetyls across the three measurement points during 
pregnancy. 
  
Model 1 
 
Model  2 
 
Model 3 
Estimate in 
SD units* 
95% CI P 
Estimate in 
SD units* 
95% CI P 
Estimate in 
SD units* 
95% CI P 
High-sensitivity C-reactive protein (SD units) (outcome) 
History of depression diagnosis 
before pregnancy (yes vs. no) 
         
    from HILMO 0.69 0.26, 1.11 0.002 0.50 0.08, 0.92 0.02 0.16 -0.21, 0.53 0.40 
    from self-reports 0.56 0.17, 0.94 0.005 0.47 0.10, 0.85 0.01 0.28 -0.05, 0.60 0.09 
Depressive symptoms  
during pregnancy 
         
    continuous score (SD units) 0.06 0.00, 0.13 0.05 0.06 0.00, 0.13 0.05 0.05 -0.01, 0.11 0.14 
    binary score (continuous 
    score≥16, probable clinical 
    depression vs. continuous 
    score<16, no probable clinical 
    depression) 
0.28 0.03, 0.53 0.03 0.28 0.04, 0.52 0.02 0.20 -0.01, 0.42 0.06 
Glycoprotein acetyls (SD units) (outcome) 
History of depression diagnosis 
before pregnancy (yes vs. no) 
         
    from HILMO 0.52 0.12, 0.93 0.01 0.42 0.01, 0.84 0.04 0.04 -0.32, 0.39 0.84 
    from self-reports 0.30 -0.06, 0.66 0.10 0.24 -0.11, 0.60 0.18 0.04 -0.26, 0.34 0.78 
Depressive symptoms  
during pregnancy 
         
    continuous score (SD units) 0.05 -0.01, 0.11 0.10 0.05 -0.01, 0.11 0.10 0.04 -0.02, 0.09 0.23 
    binary score (continuous 
    score≥16, probable clinical 
    depression vs. continuous 
    score<16, no probable clinical 
    depression) 
0.25 0.02, 0.46 0.04 0.25 0.02, 0.48 0.03 0.19 -0.008, 0.38 0.06 
Note. *Estimates and 95% Confidence Intervals (95% CI) reflect differences between those with and without a history of depression diagnosis before pregnancy or with and 
without probable clinical depression during pregnancy in high-sensitivity C-reactive protein (hsCRP) and glycoprotein acetyls in standard deviation (SD) units or change in SD 
units in hsCRP and glycoprotein acetyls per SD unit change in the continuous depressive symptom scores during pregnancy.   
Model 1 is unadjusted for covariates but includes the gestational week when blood was sampled as a within-person time-varying predictor, Model 2 is Model 1 + age and 
education, Model 3 is Model 2 + body mass index in early pregnancy (categorized as normal weight [<25 kg/m2], overweight [25-29.99 kg/m2] and obese [≥30kg/m2]).  
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Table ST1. Summary of study characteristics, main findings of cross-sectional and cohort studies testing associations between maternal depression and inflammation during pregnancy 
and the quality of evidence according to the Newcastle-Ottava Scale criteria. 
Study Population 
Sample 
Size 
Study 
Design 
Depression 
Measure 
Time of 
Depression 
Measure 
Inflam-
mation 
Markers 
Time of 
Inflamma-
tion 
Measure 
Important 
Covari-
ates 
Results 
Quality of evidence 
Selection Comparability Outcome Overall1 
CROSS-SECTIONAL STUDIES:  
(S
c
r
a
n
d
is
 e
t 
a
l.
, 
2
0
0
8
) 
Women 
from two 
Mid-
Atlantic 
obstetric 
clinics and 
one 
birthing 
center, 
USA 
27 
Cross-
sectional 
SIGH-SAD2 35-38 gw3 
IL-64 
CRP5 
 
35-38 gw3 None 
Higher depressive symptoms 
were significantly correlated with 
higher CRP, but not IL-6  
3/5 0/2 1/3 Poor 
(C
h
r
is
ti
a
n
 e
t 
a
l.
, 
2
0
0
9
) Women 
with low 
socioeco-
nomic 
status from 
Ohio State 
University 
Prenatal 
Clinic, 
USA 
60 
Cross-
sectional 
CES-D6 
Mean=15 
SD=4.8 
gw3 
IL-64 
TNF-α7 
Mean=15 
SD=4.8 gw3 
 
Body Mass 
Index 
Higher depressive symptoms 
were significantly associated with 
higher IL-6 but not TNF-α. 
2/5 1/2 3/3 Fair 
(C
a
ss
id
y
-B
u
sh
ro
w
 e
t 
a
l.
, 
2
0
1
2
) 
African 
American 
women  
from the 
Henry Ford 
Health 
System 
Clinics, 
Detroit 
area, USA 
 
187 
Cross-
sectional 
CES-D6 
13.1-28.6 
gw3 
IL-64 
IL-1β4 
IL-104 
hs-CRP5 
TNF-α7 
 
13.1-28.6  
gw3 
Body Mass 
Index  
Higher  depressive symptoms 
were significantly associated with 
higher IL-1β but not with hsCRP, 
IL-6 or TNF- α levels.   Body 
Mass Index moderated the 
associations: higher depressive 
symptoms  were associated with 
higher IL-6 and IL-10 in women 
with lower  Body Mass Index, 
while higher depressive 
symptoms were associated with 
lower IL-10  in women with 
higher  Body Mass Index. 
3/5 2/2 3/3 Fair 
(C
h
e
n
g
 a
n
d
 P
ic
k
le
r
, 
2
0
1
4
) 
Women 
from a 
prenatal 
clinic of a 
large, urban 
medical 
center, 
Ohio area, 
USA 
12 
Cross-
sectional* 
CES-D6 ≥36 gw3  
IL-1β4 
IL-54 
IL-74 
TNF-α7 
MIP-1β8 
VEGF9 
MCP-110 
G-CSF11 
≥36 gw3 None 
Higher depressive symptoms 
were associated with higher 
 MIP-1β, but not with TNF-α, IL-
1β, IL-5, IL-7, VEGF, MCP-1 or 
G-CSF.  
1/5 0/2 1/3 Poor 
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(S
im
p
so
n
 e
t 
a
l.
, 
2
0
1
6
) 
Women 
from 
Women’s 
Health 
Concerns 
Clinic, 
Ontario, 
Canada 
33 
Cross-
sectional* 
EPDS12 ≥26  gw3 
IL-64 
IL-104  
CRP5 
TNF-α7 
 
≥26 gw3 
Body Mass 
Index; 
Exclusion 
criteria: 
hyperten-
sive 
disorders, 
diabetes 
No significant associations 
between depressive symptoms 
and CRP, IL-6, TNF-α or IL-10. 
2/5 2/2 2/3 Fair 
COHORT STUDIES: 
(B
la
c
k
m
o
re
 e
t 
a
l.
, 
2
0
1
1
) 
 
Women at 
low to 
medium 
obstetric 
risk from 
the 
University 
of 
Rochester 
Clinical 
Research 
Center, 
New York, 
USA 
 
130 for 
IL-64, 
137 for 
TNF-α7 
Cohort 
SCID13 
diagnosis of 
major 
depressive 
disorder 
EPDS12 
18 and 32 
gw3 
IL-64 
TNF-α7 
18 and 32  
gw3 
Body Mass 
Index 
No significant associations of 
depression diagnosis or 
depressive symptoms with IL-6 
or TNF-α at either measurement 
point. 
4/4 1/2 3/3 Good 
(A
z
a
r
 a
n
d
 M
e
rc
e
r,
 2
0
1
3
) 
Caucasian 
women, 
low to 
medium 
socioeco-
nomic 
status from 
Cumber-
land 
Regional 
Health Care 
Center, 
Canada 
27 Cohort PHQ-914 
7-10 and 
16-20 gw3 
IL-64 
CRP5 
TNF-α7  
 
7-10 and 
16-20 gw3 
Exclusion 
criteria: 
hyperten-
sive 
disorders 
Higher depressive symptoms in 
early pregnancy were associated 
with higher CRP and TNF-α in 
early and mid-pregnancy and 
with higher IL-6 in mid-
pregnancy. An increase in 
depressive symptoms from early 
to mid-pregnancy was also 
associated with higher IL-6 in 
mid-pregnancy. 
1/4 0/2 3/3 Poor 
(H
a
e
ri
 e
t 
a
l.
, 
2
0
1
3
) 
Women  
from  
Perinatal 
Mood 
Disorders 
Clinic and 
who 
delivered at 
a single 
tertiary 
hospital, 
Texas, 
USA 
200 Cohort  
Major 
Depressive 
Disorder 
diagnosis  
EPDS12  
Major 
Depressive 
Disorder 
diagnosis 
during 
pregnancy  
EPDS11: 
12.7 gw3   
IL-64 
TNF-α7 
11-14 gw3 
Body Mass 
Index, 
Exclusion 
criteria: 
hyperten-
sive 
disorders, 
diabetes, 
infections 
Women with depression diagnosis 
had higher TNF- α and IL-6 levels 
than controls with no depression 
as indicated by EPDS. 
 
2/4 2/2 2/3 Fair 
(G
u
st
a
fs
s
o
n
 e
t 
a
l.
, 
2
0
1
8
) 
Women 
with 
familial or 
personal 
history of 
68 Cohort 
 
CES-D6 
 
24 and 37 
gw3 
IL-64 
TNF-α7 
MCP-110 and 
a latent 
variable 
37 gw3 
Exclusion 
criteria: 
high-risk or 
medically 
compli-
Higher depressive symptoms 
were associated with higher IL-6 
and TNF-α, but not with MCP-1. 
Higher depressive symptoms 
were also associated with the 
0/4 0/2 2/3 Poor 
 ADHD 
from large 
hospital 
clinic, 
Oregon, 
USA 
combining all 
three markers 
cated 
pregnancy 
latent antenatal inflammation 
variable. 
(O
sb
o
r
n
e 
et
 a
l.
, 
2
0
1
8
) 
Women 
from  
Maudsley 
Perinatal 
Psychiatry 
Service or 
routine 
antenatal 
ultrasound 
screening at 
King’s 
College 
Hospital, 
London, 
UK 
106 Cohort 
SCID13 
diagnosis of 
major 
depressive 
disorder 
BDI15 
major 
depressive 
disorder 
diagnosis 
25  gw3 
BDI 32 
gw3  
IL-24 
IL-84 
IL-64 
IL-104 
IL-1β4 
hs-CRP5 
TNF-α7 
VEGF9 
MCP-110 
EGF16 
 
23.9-34.9 gw3 
Body Mass 
Index, 
exclusion 
criteria: 
gestational 
diabetes, 
hyperten-
sion 
Women with major depressive 
disorder had higher IL-6, IL-10, 
TNF-α and VEGF, but no 
differences in  IL-2,  IL-1β,  
hsCRP, TNF- α, MCP-1 or EGF. 
2/4 2/2 2/3 Fair 
1 The quality of evidence assessments followed the Newcastle-Ottawa Scale (NOS)-criteria for cross-sectional (Wells et al., 2014b) and cohort (Wells et al., 2014a) studies. Overall quality of evidences for 
cross-sectional studies:  Good quality: 4–5 points in the selection domain, 1–2 points in the comparability domain, and 2–3 points in the outcome domain. Fair quality: 3 points in the selection domain, 1–2 
points in the comparability domain, and 2–3 points in the outcome domain. Poor quality: 1–2 points in the selection domain, or 0 points in the comparability domain, or 0–1 point(s) in the outcome domain; 
Overall quality of evidence for cohort studies: Good quality: 3–4 points in the selection domain, 1–2 points in the comparability domain, and 2–3 points in the outcome domain. Fair quality: 2 points in the 
selection domain, 1–2 points in the comparability domain, and 2–3 points in the outcome domain. Poor quality: 0–1 points in the selection domain, or 0 points in the comparability domain, or 0–1 point(s) 
in the outcome domain. . Quality of evidence according to the NOS-criteria were reviewed independently by Rachel Robinson and by Marius Lahti-Pulkkinen and Polina Girchenko. In cases of 
disagreement, they were discussed and agreed upon by consensus. 
2Structured Interview Guide for the Hamilton Depression Rating Scale- Seasonal Affective Disorder 
3gw refers to gestational week. 
4IL refers to Interleukin-2 / Interleukin-4 / Interleukin-5 / Interleukin-6 / Interleukin-7 / Interleukin-8 / Interleukin-10 / Interleukin-1β 
5hsCRP / CRP refers to high sensitivity C-Reactive Protein / C-reactive Protein 
6CES-D refers to Center for Epidemiological Studies Depression Scale 
7TNF-α refers to Tumor Necrosis Factor alpha 
8MIP-1β refers to Macrophage Inflammatory Protein 1β 
9VEGF refers to Vascular Endothelial Growth Factor 
10MCP-1 refers to Monocyte Chemoattractant Protein-1 
11G-CSF refers to Granulocyte-Colony Stimulating Factor 
12EPDS refers to Edinburgh Postnatal Depression Scale 
13SCID refers to Structured Clinical Interview for DSM-IV 
14PHQ-9 refers to Patient Health Questionnaire-9 
15BDI refers Beck Depression Scale 
16EGF refers Epidermal Growth Factor 
Note. Studies of Scrandis et al, 2008, Cheng and Pickler, 2014, and Simpson et al., 2016 were prospective in study design. However, all studies had only one measurement during pregnancy (prospective 
measurements were postpartum) and reported cross-sectional correlations of depression and inflammation during pregnancy. Therefore, these studies were classified as cross-sectional. Studies of Haeri, et 
al.,, 2013, and Osborne et al., 2018 were classified by the authors as case-control. However, after assessment, we judged that the studies should not be assessed as a classical case-control studies,  but should 
be assessed using the criteria of cohort studies. Haeri, Baker, and Ruano, 2013. compared women with major depressive disorder diagnosis at any time during pregnancy with controls without clinically 
relevant depressive symtpoms in early pregnancy (control group was not assessed for depression at any later stage during pregnancy). Moreover, in this study inflammatory biomarkers were assessed 
before, at the time of or after the case-control status definition. In the Osborne et al., 2018, the cases comprised 49 women with major depressive disorder. However, 18 of the cases did not meet the 
diagnostic criteria for major depressive disorder when assessed during pregnancy. 
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 Table ST2. Newcastle–Ottawa scale for assessment of quality of cross-sectional studies (each asterisk represents if individual criterion within the subsection was fulfilled) testing 
associations between depression and inflammation during pregnancy. 
Quality assessment criteria Acceptable(★) 
Scrandis et al., 
2008* 
Christian et al., 
2009 
Cassidy-
Bushrow et al., 
2012 
Cheng and 
Pickler, 2014* 
Simpson et al., 
2016* 
Selection       
Representativeness of the 
sample? 
Representative of average pregnant women, 
(age/being at risk of disease, generalizability, 
random or non-random sampling) 
- - ★ - - 
Selected group of users No inflammatory disease ★ ★ - - ★ 
Sample size Justified and Satisfactory - - ★ - - 
Diagnose 
Structured Interview Depression Diagnosis ★★ 
Health Record Diagnosis or Validated Symptom 
Scale ★ 
★★ ★ ★ ★ ★ 
Comparability       
Comparability of cohorts on the 
basis of the design or analysis 
Study controls for body mass index - ★ ★ - ★ 
Study controls for additional 
risk factors? 
Study Controls for hypertensive disorders  and/or 
diabetes disorders 
- - ★ - ★ 
Outcome       
Assessment of the Method 
Validated Inflamation Assessment★★ 
Non-validated, clearly defined inflammation 
assessment★ 
★ ★★ ★★ ★ ★★ 
Statistical Test 
The statistical assessment is clearly described, 
provides measurement error, confidence interval and 
probability level 
- ★ ★ - - 
Overall quality score (maximum= 10) 4 6 8 2 6 
*Studies by Scrandis et al, 2008, Cheng and Pickler, 2014, and Simpson et al., 2016 were prospective in design. However, all studies had only one measurement during pregnancy 
(prospective measurements were postpartum) and reported cross-sectional correlations of depression and inflammation during pregnancy Thus, we classified them as cross-sectional. 
Note. Quality of evidence according to the NOS-criteria for cross-sectional studies (Anthony and Lin, 2018; Herzog et al., 2013) were reviewed independently by Rachel Robinson 
and by Marius Lahti-Pulkkinen and Polina Girchenko. In cases of disagreement, they were discussed and agreed upon by consensus. 
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 Table ST3. Newcastle–Ottawa scale for assessment of quality of cohort studies (each asterisk represents if individual criterion within the subsection was fulfilled) testing associations 
between maternal depression and inflammation during pregnancy. 
Quality assessment criteria Acceptable(★) 
Blackmore et 
al., 2011 
Azar and 
Mercer, 2013 
Haeri et al,, 
2013* 
Gustafsson et 
al., 
2018 
Osborne et al., 
2018* 
Selection 
Representativeness of the exposed 
cohort? 
Representative of average pregnant 
women (age/being at risk of disease, 
sample size, generalizability) 
★ - - - - 
Selection of the non-exposed cohort? 
Drawn from same community as 
exposed cohort 
★ ★ - - - 
Ascertainment of exposure 
Depression Diagnosis in health records, 
structured interview 
★ - ★ - ★ 
Demonstration that outcome of 
interest was not present at start of 
study 
No inflammatory disease ★ - ★ - ★ 
Comparability 
Comparability of cohorts on the basis 
of the design or analysis 
Study controls for body mass index ★ - ★ - ★ 
Study controls for additional risk 
factors? 
Study controls for hypertensive and/or 
diabetes disorders 
- - ★ - ★ 
Outcome 
Assessment of outcome 
Independent blind assessment of 
inflammation 
★ ★ ★ ★ ★ 
Was follow-up long enough for 
outcomes to occur 
At least two inflammation asessments at 
different gestational stages 
★ ★ - - - 
Adequacy of follow up of cohorts 
Complete follow-up, or subjects lost to 
follow-up unlikely to introduce bias 
(>60% follow up, or description 
provided of those lost) 
★ ★ ★ ★ ★ 
Overall quality score (maximum=9) 8 4 6 2 6 
* Studies of Haeri, et al.,, 2013, and Osborne et al., 2018 were classified by the authors as case-control. However, after assessment, we judged that the studies should not be assessed as a classical case-control 
studies,  but should be assessed using the criteria of cohort studies. Haeri, Baker, and Ruano, 2013. compared women with major depressive disorder diagnosis at any time during pregnancy with controls 
without clinically relevant depressive symtpoms in early pregnancy (control group was not assessed for depression at any later stage during pregnancy). Moreover, in this study inflammatory biomarkers were 
assessed before, at the time of or after the case-control status definition. In the Osborne et al., 2018, the cases comprised 49 women with major depressive disorder. However, 18 of the cases did not meet the 
diagnostic criteria for major depressive disorder when assessed during pregnancy. Note. Quality of evidence according to the NOS-criteria for cohort studies (Wells et al., 2014a, b) were reviewed 
independently by Rachel Robinson and by Marius Lahti-Pulkkinen and Polina Girchenko. In cases of disagreement, they were discussed and agreed upon by consensus. 
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 Table ST4. Associations between moderators and covariates and high-sensitivity C-reactive protein and glycoprotein acetyls during pregnancy.  
 
Moderator / Covariate (predictor): 
Mean 
difference 
in standard 
deviation 
units 
 
95% 
Confidence 
Interval 
 
 
 
P 
P for interaction 
between moderator / 
covariate x  gestational 
week at the time of 
blood sampling 
 
 
Mean difference 
in raw units 
 
95% Confidence 
Interval 
in raw units 
High-sensitivity C-reactive protein (outcome) mg/L mg/L 
Age < 40 vs. ≥ 40 years -0.41 -0.71, -0.11 0.008 0.01 -1.54 -2.66, -0.43 
Secondary or lower vs. tertiary 
education 
0.41 0.23, 0.58 <0.0001 0.44 1.71 1.04, 2.37 
Smoking during pregnancy       
   No Ref      
   Quit during first trimester 0.02 -0.43, 0.46 0.94 0.76 0.10 -1.55, 1.74 
   Smoked throughout pregnancy -0.55 -1.29, 0.19 0.14 0.20 -0.36 -3.08, 2.36 
Alcohol use during pregnancy vs. no 
alcohol use during pregnancy 
0.05 -0.23, 0.33 0.73 0.89 0.57 -0.41, 1.54 
Body mass index in early pregnancy        
   Normal weight (<24.99 kg/m2) Ref      
   Overweight (25-29.99 kg/m2) 0.67 0.47, 0.87 <0.0001 0.62 2.23 1.33, 3.12 
   Obese (≥30 kg/m2) 1.12 0.94, 1.30 <0.0001 0.95 5.16 4.44, 5.89 
Hypertensive disorders       
    Normotension Ref      
    Gestational hypertension  0.23 -0.08, 0.55 0.15 0.46 1.11 -0.06, 2.29 
    Pre-eclampsia  0.31 0.003, 0.63 0.05 0.37 1.33 0.16, 2.49 
    Chronic hypertension 0.41 0.16, 0.66 0.001 0.28 1.57 0.64, 2.49 
Diabetes disorders       
    No Ref  Ref    
    Gestational diabetes 0.38 0.16, 0.61 0.0009 0.97 1.58 0.75, 2.42 
    Type 1 diabetes 0.10 -0.50, 0.70 0.74 0.84 3.37 1.15, 5.60 
Glycoprotein acetyls (outcome)  mmol/L mmol/L 
Age < 40 vs. ≥ 40 years -0.15 -0.52, 0.21 0.41 0.96 -0.04 -0.07, 0.001 
Secondary or lower vs. tertiary 
education 
0.24 0.02, 0.45 0.03 0.45 0.06 0.03, 0.09 
Smoking during pregnancy       
   No Ref      
   Quit during first trimester 0.18 -0.36, 0.71 0.52 0.52 0.03 -0.02, 0.08 
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   Smoked throughout pregnancy -0.22 -1.05, 0.62 0.61 0.72 -0.01 -0.10, 0.07 
Alcohol use during pregnancy vs. no 
alcohol use during pregnancy 
0.16 -0.16, 0.48 0.33 0.91 0.57 -0.41, 1.54 
Body mass index in early pregnancy       
   Normal weight (<24.99 kg/m2) Ref      
   Overweight (25-29.99 kg/m2) 0.56 0.30, 0.82 <0.0001 0.01 0.14 0.12, 0.17 
   Obese (≥30 kg/m2) 0.99 0.77, 1.22 <0.0001 0.84 0.19 0.17, 0.21 
Hypertensive disorders        
    Normotension Ref      
    Gestational hypertension  0.08 -0.28, 0.43 0.67 0.31 0.04 0.001, 0.07 
    Pre-eclampsia  0.63 0.28, 0.98 0.0005 0.17 0.09 0.05, 0.12 
    Chronic hypertension 0.78 0.50, 1.07 <0.0001 0.11 0.11 0.08, 0.13 
Diabetes disorders       
    No Ref  Ref    
    Gestational diabetes 0.48 0.22, 0.74 0.0003 0.34 0.11 0.08, 0.13 
    Type 1 diabetes -0.46 -1.13, 0.22 0.18 0.08 -0.01 -0.08, 0.06 
Table ST5. Associations of a history of depression diagnosis before pregnancy derived from the Care Register for 
Healthcare (HILMO) and self-reports, and depressive symptoms and probable clinical depression reported during 
pregnancy with high-sensitivity C-Reactive protein and glycoprotein acetyls across the three measurement points 
during pregnancy. Model includes the gestational week when blood was sampled as a within-person time-varying 
predictor and age, education, and diabetes and hypertensive disorders during pregnancy. 
 Estimate in SD units* 95% CI P 
High-sensitivity C-reactive protein (SD units) (outcome) 
History of depression diagnosis before pregnancy 
(yes vs. no) 
   
    from HILMO 0.51 0.09, 0.93 0.02 
    from self-reports 0.50 0.12, 0.87 0.009 
Depressive symptoms during pregnancy    
    continuous score (mean of reports at 3 blood 
    sampling points in SD units) 
0.28 0.04, 0.52 0.02 
    binary score (continuous score≥16,  
    probable clinical depression  
    vs. continuous score<16,  
    no probable clinical depression) 
0.07 0.003, 0.13 0.04 
Glycoprotein acetyls (SD units) (outcome) 
History of depression diagnosis 
before pregnancy (yes vs. no) 
   
    from HILMO 0.43 0.05, 0.82 0.03 
    from self-reports 0.31 -0.02, 0.64 0.07 
Depressive symptoms during pregnancy    
    continuous score (mean of reports at 3 blood 
    sampling points in SD units) 
0.18 -0.02, 0.37 0.07 
    binary score (continuous score≥16,  
    probable clinical depression  
    vs. continuous score<16,  
    no probable clinical depression) 
0.05 -0.01, 0.11 0.08 
Note. *Estimates and 95% Confidence Intervals (95% CI) reflect differences between those with and without a 
history of depression diagnosis before pregnancy or with and without probable clinical depression during 
pregnancy in high-sensitivity C-reactive protein (hsCRP) and glycoprotein acetyls in standard deviation (SD) units 
or change in SD units in hsCRP and glycoprotein acetyls per SD unit change in the continuous depressive 
symptoms score during pregnancy.   
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 Table ST6. Associations of a history of depression diagnosis before pregnancy derived from the Care Register for 
Healthcare (HILMO) and self-reports, and depressive symptoms and probable clinical depression reported during 
pregnancy with high-sensitivity C-Reactive protein and glycoprotein acetyls across the three measurement points 
during pregnancy. Sensitivity analyses excluding blood samples which occurred within a month preceding or 
following acute infectious disease diagnoses derived from HILMO. 
 Estimate in SD units* 95% CI P 
High-sensitivity C-reactive protein (SD units) (outcome) 
History of depression diagnosis 
before pregnancy (yes vs. no) 
   
    from HILMO** 0.70 0.27, 1.12 0.001 
    from self-reports*** 0.57 0.18, 0.95 0.004 
Depressive symptoms during pregnancy    
    continuous score (mean of reports at 3 blood 
    sampling points in SD units)**** 
0.06 0.0001, 0.13 0.05 
    binary score (continuous score≥16,  
    probable clinical depression  
   vs. continuous score<16,  
    no probable clinical depression)**** 
 
0.27 
 
0.02, 0.52 
 
0.03 
Glycoprotein acetyls (SD units) (outcome) 
History of depression diagnosis 
before pregnancy (yes vs. no) 
   
    from HILMO** 0.49 0.09, 0.90 0.02 
    from self-reports*** 0.29 -0.07, 0.64 0.12 
Depressive symptoms during pregnancy    
    continuous score (mean of reports at 3 blood 
    sampling points in SD units)**** 
0.05 -0.001, 0.11 0.09 
    binary score (continuous score≥16,  
    probable clinical depression  
   vs. continuous score<16,  
    no probable clinical depression)**** 
 
0.25 
 
0.02, 0.47 
 
0.04 
Note. *Estimates and 95% Confidence Intervals (95% CI) reflect differences between those with and without a 
history of depression diagnosis before pregnancy or with and without probable clinical depression during 
pregnancy in high-sensitivity C-reactive protein (hsCRP) and glycoprotein acetyls in standard deviation (SD) units 
or change in SD units in hsCRP and glycoprotein acetyls per SD unit change in the continuous depressive 
symptoms score during pregnancy.   
** 13 measurements were excluded out of a total of 1125 measurements in the analytic sample (n=375). 
 *** 11 measurements were excluded out of a total of 1041 measurements in the analytic sample (n=347). 
  **** 6 measurements were excluded out of a total of 885 measurements in the analytic sample (n=295). 
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